Area of research
Infectious Diseases · Virology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, HIV Research and Treatment, and Animal Virus Infections Studies.
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2
Host cell entry and neutralisation sensitivity of SARS-CoV-2 BA.3.2
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation
Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and Its Variants Displaying Potent Antiviral Activity
Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies
Structural Characterization and AI‐Enhanced Modeling of a Broadly Neutralizing Camelid Antibody Against SARS‐CoV‐2 Variants
SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency
Phosphatidylserine-exposing extracellular vesicles in body fluids are an innate defence against apoptotic mimicry viral pathogens
Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC
Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination
Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models
ACE2-independent sarbecovirus cell entry can be supported by TMPRSS2-related enzymes and can reduce sensitivity to antibody-mediated neutralization
A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants
Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination
Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3
Viral immunity: Basic mechanisms and therapeutic applications—a Keystone Symposia report
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination
The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses
SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture
SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination